ProCyte Corp. (NASDAQ:PRCY) announced Wednesday that itsscientists have developed a specific method of rapidly selectingformulations for its hair growth technology. Data werepresented at the Third International Conference of thePrediction of Percutaneous Penetration in Montpellier, France.
The Kirkland, Wash. company's peptide-copper compoundTricomin is being studied for its effect on prevention of hairloss due to androgenetic alopecia.
(c) 1997 American Health Consultants. All rights reserved.